RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
-16.09%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$1.65B
AUM Growth
+$1.65B
(-39%)
Cap. Flow
-$554M
Cap. Flow
% of AUM
-33.52%
Top 10 Holdings %
Top 10 Hldgs %
45.81%
Holding
77
New
–
Increased
9
Reduced
35
Closed
14
Top Buys
| 1 |
Replimune Group
REPL
|
$16.5M |
| 2 |
Cogent Biosciences
COGT
|
$7.06M |
| 3 |
Intuitive Surgical
ISRG
|
$4.58M |
| 4 |
Annexon
ANNX
|
$4.53M |
| 5 |
Establishment Labs
ESTA
|
$4.48M |
Top Sells
| 1 |
Krystal Biotech
KRYS
|
$89.5M |
| 2 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
$83.3M |
| 3 |
Atara Biotherapeutics
ATRA
|
$74.9M |
| 4 |
Abbott
ABT
|
$29.8M |
| 5 |
Align Technology
ALGN
|
$28.6M |
Sector Composition
| 1 | Healthcare | 99.13% |
| 2 | Industrials | 0.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Absci
ABSI
$351M
| $25.4M | 1.54% |
8,253,316
| – | – |
|
27
Keros Therapeutics
KROS
$642M
| $25.2M | 1.53% |
552,506
| – | – |
|
28
ALX Oncology
ALXO
$54.1M
| $24.3M | 1.47% |
4,036,451
-290,058
| -7% | -$1.75M |
|
29
4D Molecular Therapeutics
FDMT
$293M
| $22.5M | 1.36% |
1,073,435
-187,992
| -15% | -$3.95M |
|
30
Shattuck Labs
STTK
$61.3M
| $21.7M | 1.31% |
5,615,489
| – | – |
|
|
IGMS
31
DELISTED
IGM Biosciences
IGMS
| $21.1M | 1.28% |
3,072,478
| – | – |
|
32
Immunovant
IMVT
$2.89B
| $19M | 1.15% |
720,177
-249,444
| -26% | -$6.59M |
|
|
33
Intuitive Surgical
ISRG
$156B
| $17.7M | 1.07% |
39,843
+10,297
| +35% | +$4.58M |
|
|
AUGX
34
DELISTED
Augmedix, Inc. Common Stock
AUGX
| $14.4M | 0.87% |
16,380,327
| – | – |
|
35
89bio
ETNB
$1.36B
| $14M | 0.85% |
1,745,656
-518,910
| -23% | -$4.16M |
|
36
Ardelyx
ARDX
$1.56B
| $13.9M | 0.84% |
1,881,501
-313,059
| -14% | -$2.32M |
|
37
Stryker
SYK
$147B
| $13.4M | 0.81% |
39,483
-3,763
| -9% | -$1.28M |
|
38
Prime Medicine
PRME
$587M
| $10.7M | 0.64% |
2,074,350
| – | – |
|
|
BPMC
39
DELISTED
Blueprint Medicines
BPMC
| $10.2M | 0.62% |
94,405
-18,655
| -17% | -$2.01M |
|
|
40
Establishment Labs
ESTA
$1.11B
| $9.68M | 0.59% |
213,024
+98,683
| +86% | +$4.48M |
|
41
Nuvation Bio
NUVB
$1.04B
| $8.85M | 0.54% |
3,031,009
| – | – |
|
42
Entrada Therapeutics
TRDA
$202M
| $7.99M | 0.48% |
560,971
-722,764
| -56% | -$10.3M |
|
43
AC Immune
ACIU
$230M
| $7.21M | 0.44% |
1,807,704
-199,327
| -10% | -$795K |
|
|
VERV
44
DELISTED
Verve Therapeutics
VERV
| $7.14M | 0.43% |
1,463,406
-141,109
| -9% | -$689K |
|
45
Repare Therapeutics
RPTX
$73.5M
| $6.41M | 0.39% |
1,942,555
-73,747
| -4% | -$243K |
|
46
Cytokinetics
CYTK
$5.89B
| $6.06M | 0.37% |
111,867
-49,733
| -31% | -$2.69M |
|
47
Ventyx Biosciences
VTYX
$185M
| $5M | 0.3% |
2,164,126
| – | – |
|
|
BOLD
48
Boundless Bio
BOLD
$25.3M
| $4M | 0.24% |
1,034,583
-79,451
| -7% | -$307K |
|
|
49
Atara Biotherapeutics
ATRA
$87.6M
| $3.84M | 0.23% |
452,270
-8,811,039
| -95% | -$74.9M |
|
50
Stereotaxis
STXS
$244M
| $3.84M | 0.23% |
2,108,219
-1,200,579
| -36% | -$2.19M |
|